Business
Closing of Global Offering and resulting TVR
Closing of Global Offering and resulting TVR.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n RNS Number : 6782T\n Renalytix AI PLC\n 21 July 2020\n \n \n \n \n \n \n \n \n \n \n \n Renalytix AI plc\n \n \n \n \n \n Closing of Global Offering and resulting total voting rights\n \n \n \n \n \n Renalytix AI plc \n (LSE\n : RENX) (NASDAQ: RNLX) (\"RenalytixAI\" or the \"Company\"), an \n artificial intelligence\n -enabled\n \n \n in vitro\n \n \n diagnostics \n company, focused on optimizing clinical management of \n kidney disease to drive improved patient outcomes and lower healthcare costs\n , \n today \n announces the closing of its global offering of an aggregate of 11,000,000 new ordinary shares, including 5,485,000 American Depositary Shares (\"ADSs\") at a price of US$13.50 per ADS and 30,000 ordinary shares at a price of £5.37 per ordinary share (at an exchange rate of GBP:USD 1:1.2563), for aggregate gross proceeds of approximately US$74.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by RenalytixAI. Each ADS offered represents two ordinary shares \n of \n the Company. The ADSs were offered in a registered public offering in the United States and the Company's ordinary shares were offered in a concurrent private placement in Europe and other countries outside of the United States (together, the \"Global Offering\"). In addition, RenalytixAI has granted the underwriters a 30-day option to purchase up to an additional 822,750 ADSs at the initial offering price per ADS less underwriting discounts and commissions.\n \n \n \n \n \n The ADSs began trading on the Nasdaq Global Market under the symbol \"RNLX\" on 17 July 2020. RenalytixAI's ordinary shares are admitted to trading on the AIM market of London Stock Exchange plc (\"AIM\") under the symbol \"RENX\". Application has been made for the new ordinary shares issued in Global Offering to be admitted to trading on AIM and it is expected that admission will become effective and dealings in the new ordinary shares will commence at 8:00 a.m. (BST) on 22 July 2020.\n \n \n \n \n \n J.P. Morgan and Stifel acted as joint global coordinators and joint book-running managers for the Global Offering. \n \n \n \n \n \n Following the closing of the Global Offering, the issued share capital of the Company is 70,416,134 ordinary shares and thi...